Credit ADOBE STOCK
More than half a million Michiganders have received a first dose of either the Pfizer or Moderna vaccine, according to the state s health department. But a smaller cohort, as participants in clinical trials, have received vaccines made by other companies.
Those studies are still underway, which means that many subjects, recruited specifically for their priority status in the vaccine line, now have the option to get one of the authorized vaccines. The people leading these trials at Michigan health systems find themselves responding in two ways.
“As a physician, this is a great problem to have, because it means that we have enough safe and effective vaccine that we can vaccinate most of our high-risk patients,” said Dr. Kathleen Linder, one of the principal investigators for the Ann Arbor VA’s arm of the Novavax trial. “But as a researcher, it is a little challenging.”